NCT01961765View on ClinicalTrials.gov

Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

May 31, 2016

Study Completion Date

January 31, 2017

Conditions
Relapsed Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Interventions
DRUG

cabozantinib

Trial Locations (2)

02215

Beth Israel Deaconess Medical Center, Boston

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

Exelixis
All Listed Sponsors
collaborator

Exelixis

INDUSTRY

lead

Massachusetts General Hospital

OTHER